This comprehensive volume explores cutting-edge technologies used to pursue systems-based pharmacogenomics. Extensive chapters follow on gene-drug interactions and the use of pharmacogenomics in therapeutics of diseases.

The Integration of Personalized and Systems Medicine.- Applications of Microarrays and Biochips in Pharmacogenomics.- Confounding in Genetic Association Studies and Its Solutions.- Pharmacogenetics of Membrane Transporters.- Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy.- Pharmacogenomics of G Protein-Coupled Receptor.- G Protein-Coupled Receptors Disrupted in Human Genetic Disease.- G Protein-Coupled Receptor Pharmacogenetics.- Epigenetic Alterations of the Dopaminergic System in Major Psychiatric Disorders.- Pharmacogenomics in Alzheimer's Disease.- Pharmacogenetics of Asthma.- From SNPs to Functional Studies in Cardiovascular Pharmacogenomics.- Pharmacogenomics in Gastrointestinal Disorders.- Pharmacogenomics in Rheumatoid Arthritis.- Cancer Pharmacogenetics.- Pharmacogenomics in the Preclinical Development of Vaccines.- Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines.

Since each human is genetically distinctive, responding differently to disease-causing factors as well as drugs, the field pharmacogenomics arose to develop personalized medicine, or medicine that deals with the complexity of the human body.  In Pharmacogenomics in Drug Discovery and Development, leading experts present methodical, state-of-the-art contributions covering topics from individual molecules to systemic diseases, examining both fundamental concepts and advanced technologies.  Divided into three sections, the volume begins by exploring cutting-edge technologies used to pursue systems-based pharmacogenomics, followed by extensive chapters on gene-drug interactions and the use of pharmacogenomics in therapeutics of diseases. Although not in standard Methods in Molecular Biology™ series format, the book retains the practicality and usefulness of the highly successful series.

Comprehensive and up-to-date, Pharmacogenomics in Drug Discovery and Development is an ideal volume for scientists striving to transform disease treatment into disease prevention.

Examines both fundamental concepts and advanced technologies in pharmacogenomics Uses cutting-edge technologies to pursue systems-based pharmacogenomics, including bioinformatics, microarray, and association studies Methodical, state-of-the-art contributions covering topics from individual molecules, gene-drug interactions, to systemic diseases presented by leading experts Explores extensive applications of pharmacogenomics in drug development for diseases including psychiatric disorders, cardiovascular diseases, cancer, Alzheimer's disease, rheumatoid arthritis, asthma, and infectious diseases Includes supplementary material: sn.pub/extras

GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com